Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.

Wu, Leilei; Ke, Linping; Zhang, Zhenshan; Yu, Jinming; Meng, Xue

Wu, Leilei; Ke, Linping; Zhang, Zhenshan; Yu, Jinming; Meng, Xue.

Afiliação

Wu L; Department of Radiation Oncology, School of Medicine, Shandong University, Jinan, China.
Ke L; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zhang Z; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yu J; Department of Radiation Oncology, School of Medicine, Shandong University, Jinan, China.
Meng X; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Front Oncol ; 10: 602762, 2020.

Article em En | MEDLINE | ID: mdl-33392095

Palavras-chave

EGFR TKI resistance; combination (combined) therapy; immune check inhibitor; mechanisms of resistance; molecular biomarkers; osimertinib; tumor immune environment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google